Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight.

As of March 2010[update], it is undergoing Phase II/III clinical trials.

[1][2] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.